Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRX-7MLL
- Development stage
- Discontinued
- Lead developer
- MEDRx
- Modality
- Small Molecules
- Administration
- Transdermal
01
Overview
MRX-7MLL is a transdermal patch formulation of memantine developed by MEDRx for the treatment of Alzheimer's disease. It utilizes the proprietary Nano-Sized Colloid Transdermal System (NCTS) technology to deliver memantine, an NMDA receptor antagonist, through the skin. This delivery method is designed to maintain stable plasma levels and reduce gastrointestinal side effects associated with oral administration. Development of MRX-7MLL has been discontinued.
- Other names
- memantine transdermal patch
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on MRX-7MLL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRX-7MLL.